Carboplatin, as well as other platinum derivatives, may also be good chemotherapeutic agents for basal-like breast cancers due to the implicated function of the BRCA1-pathway in this subtype because BRCA1 mutation carriers are likely to develop tumors of the basal-like phenotype [3,39,40]. Here, BRCA1 is linked to breast cancer.